Recent Updates
Recently added Catalysts

OMS302

Phase 3

Unilateral Cataract Extraction | Small molecule | Rare Disease |Omeros Corporation|Last Updated: Jul 22, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment78
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02132312A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens ReplacementPHASE3 COMPLETED 78Jul 1, 2014Sep 12, 2016Jul 22, 202111 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Intraoperative Pupil Diameter
From surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure), the mean time of surgery duration is 35.46 minutes with a standard deviation of 19.98.

Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm/min) During Surgery Excluding Subjects with In-evaluable Videos.

Acute Postoperative Pain
24 hours

Mean AUC Analysis of Postoperative pain as measured using the Alder Hey Triage Pain Score at 3, 6, 9, and 24 hours after surgery. The primary analysis of Alder Hey Triage Pain Score was similar to the primary analysis of the change in pupil diameter using AUC. The Alder Hey Triage Pain Score identifies five categories of observations: voice/cry, facial expression, posture, movement, and color. Each of these has a possible score of 0, 1, or 2, resulting in a total score ranging between 0 and 10. A total score of zero means the subject experienced no pain, as the 5 categories added up totals zero. A total score of 10 means the subject experienced a lot of pain and is the worst possible outcome, as the 5 categories added up totals 10. Parent responses in a diary with a score of 0, 1, or 2. 1. Cry or voice, 0=no compliant/cry, 1=Consolable, 2=Inconsolable 2. Facial Expression, 0=Normal, 1=Short grimace \<50% of time, 2=Long grimace \>50% of time 3. Posture, 0=Normal, 1=Touching/rub

Safety as Measured by Treatment-emergent Adverse Events, the Number of Affected Patients/at Risk (%) and the Number of Events.
90 days

Safety as assessed by the incidence of adverse events and serious adverse events up until the last visit at Day 90.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
OMS302EXPERIMENTALOMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
Phenylephrine HClACTIVE_COMPARATORPhenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
Interventions
NameTypeDescription
OMS302DRUG -
Phenylephrine HClDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range1 Day — 47 Months
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: 1. Are 0 through three years of age at the time of surgery. 2. Are to undergo unilateral primary cataract extraction with or without lens replacement. 3. Have informed consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization provided by a parent or l...

Countries:United States
Unlock Eligibility Criteria